Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MARK RICHARD A						2. Issuer Name and Ticker or Trading Symbol Viatris Inc [VTRS]									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) 1000 MYLAN BOULEVARD					3. Date of Earliest Transaction (Month/Day/Year) 11/16/2020									Officer below)	(give title		Other (s below)	specify	
(Street) CANONSBURG PA 15317 (City) (State) (Zip)				4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Non	ı-Deriv	/ative	Se	curitie	s Ac	cquired,	Disp	osed o	of, or B	enef	iciall	y Owned	k			
1. Title of Security (Instr. 3) 2. Trans Date (Month/			saction	ear) i	2A. Deemed Execution Date, if any (Month/Day/Year		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3,		A) or	5. Amou Securitie Benefici Owned I	nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) (D)	or I	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock ⁽¹⁾				11/10	6/202	0			A		9,228	8	1	(2)	9,	228	D		
		T	able II - I												Owned				
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, Transaction of Expiration Date y or Exercise (Month/Day/Year) if any Code (Instr. Derivative (Month/Day/Year)					Amount of				8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owner Form: Direct or Indi (I) (Ins	Ownership	Beneficial Ownership ect (Instr. 4)					
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or Nu of	mber ares					
Non- Employee Director Stock Option - Right to Buy ⁽³⁾	\$18.32	11/16/2020			A		6,109		(4)	06	5/21/2029	Commo Stock	6,	109	(3)	6,109		D	
Non- Employee Director Stock Option -	\$ 17.48	11/16/2020			A		6,151		(5)	03	3/02/2030	Commo	6,	151	(3)	6,151		D	
Right to Buy ⁽³⁾		11/10/2020										Stock							

Explanation of Responses:

- 1. On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).
- 2. Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was \$15.85 per share.
- 3. Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.
- 4. These options vested on March 2, 2020.
- 5. These options will vest on March 2, 2021.
- 6. Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.
- 7. Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

Remarks:

Units(6)

/s/ Kevin Macikowski, by power of attorney

11/18/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

** Signature of Reporting Person

Date

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.